Electroretinographic effects of an intravitreal injection of triamcinolone in rabbit retina

被引:37
作者
Dierks, D
Lei, B
Zhang, KQ
Hainsworth, DP
机构
[1] Univ Missouri, Mason Eye Inst, Columbia, MO 65212 USA
[2] Univ Missouri, Coll Vet Med, Dept Vet Med & Surg, Columbia, MO 65212 USA
关键词
D O I
10.1001/archopht.123.11.1563
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Objective: To investigate the clinical, histologic, and electroretinographic effects of intravitreal injection of triamcinolone acetonide suspension in the rabbit retina. Methods: Three groups of 6 rabbits each received intravitreal injections. Group I received 4 mg of triamcinolone acetonide, group 2 received an equal volume (0.1 mL) of the corticosteroid supernatant, and group 3 received 4 mg of triamcinolone acetonide with the supernatant replaced with balanced salt solution. Uninjected left eyes served as controls. Electroretinograms were obtained at baseline and at 3 to 4 and 6 to 7 days after injection of triamcinolone. Enucleated eyes were examined histologically. Results: Ocular examination revealed no differences among the 3 groups. When subjected to stimulation with moderate to high flash intensities, eyes that had received intravitreal injections of triamcinolone (groups 1 and 3) had a 10% to 25% increase in dark-adapted a- and b-wave electroretinographic amplitudes. No histologic differences were observed between injected and control eyes. Conclusions: Intravitreal injection of 4 mg of triamcinolone acetonide does not cause a toxic reaction in the rabbit retina after 7 days. Triamcinolone therapy may augment the rod-driven electroretinographic responses, suggesting a mechanism by which visual function may improve. Clinical Relevance: Evaluation of the toxic effects of triamcinolone is useful because of increased applications of intravitreal injection.
引用
收藏
页码:1563 / 1569
页数:7
相关论文
共 33 条
[1]   Intravitreal triamcinolone acetonide for the management of diabetic papillopathy [J].
Al-Haddad, CE ;
Jurdi, FA ;
Bashshur, ZF .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2004, 137 (06) :1151-1153
[2]   Intravitreal preservative-free triamcinolone acetonide for the treatment of macular oedema [J].
Bakri, SJ ;
Shah, A ;
Falk, NS ;
Beer, PM .
EYE, 2005, 19 (06) :686-688
[3]  
BIRCH DG, 1984, INVEST OPHTH VIS SCI, V25, P236
[4]   Encapsulated cell-based intraocular delivery of ciliary neurotrophic factor in normal rabbit: Dose-dependent effects on ERG and retinal histology [J].
Bush, RA ;
Lei, B ;
Tao, W ;
Raz, D ;
Chan, CC ;
Cox, TA ;
Santos-Muffley, M ;
Sieving, PA .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2004, 45 (07) :2420-2430
[5]  
BUSH RA, 1994, INVEST OPHTH VIS SCI, V35, P635
[6]   Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up [J].
Challa, JK ;
Gillies, MC ;
Penfold, PL ;
Gyory, JF ;
Hunyor, ABL ;
Billson, FA .
AUSTRALIAN AND NEW ZEALAND JOURNAL OF OPHTHALMOLOGY, 1998, 26 (04) :277-281
[7]   Intravitreal triamcinolone for the treatment of refractory diabetic macular oedema with hard exudates: an optical coherence tomography study [J].
Ciardella, AP ;
Klancnik, J ;
Schiff, W ;
Barile, G ;
Langton, K ;
Chang, S .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2004, 88 (09) :1131-1136
[8]  
Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
[9]   EXPERIMENTAL AND CLINICAL OBSERVATIONS OF THE INTRAOCULAR TOXICITY OF COMMERCIAL CORTICOSTEROID PREPARATIONS [J].
HIDA, T ;
CHANDLER, D ;
ARENA, JE ;
MACHEMER, R .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1986, 101 (02) :190-195
[10]  
HOOD DC, 1990, INVEST OPHTH VIS SCI, V31, P2070